MX2018009100A - Metodos para modular la flora intestinal. - Google Patents
Metodos para modular la flora intestinal.Info
- Publication number
- MX2018009100A MX2018009100A MX2018009100A MX2018009100A MX2018009100A MX 2018009100 A MX2018009100 A MX 2018009100A MX 2018009100 A MX2018009100 A MX 2018009100A MX 2018009100 A MX2018009100 A MX 2018009100A MX 2018009100 A MX2018009100 A MX 2018009100A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- glp
- defensins
- intestinal microbiota
- analogs
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 244000005709 gut microbiome Species 0.000 title abstract 2
- 102000000541 Defensins Human genes 0.000 abstract 2
- 108010002069 Defensins Proteins 0.000 abstract 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 abstract 1
- 108010019598 Liraglutide Proteins 0.000 abstract 1
- -1 Liraglutide Chemical class 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 241000736262 Microbiota Species 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001280 Prediabetic State Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 102000012265 beta-defensin Human genes 0.000 abstract 1
- 108050002883 beta-defensin Proteins 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000007952 growth promoter Substances 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 229960002701 liraglutide Drugs 0.000 abstract 1
- 235000013372 meat Nutrition 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 244000144977 poultry Species 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201670041 | 2016-01-26 | ||
| DKPA201670483 | 2016-07-01 | ||
| PCT/DK2017/050017 WO2017129195A1 (en) | 2016-01-26 | 2017-01-26 | Methods for modulating intestinal microbiota |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009100A true MX2018009100A (es) | 2019-02-28 |
Family
ID=58056942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009100A MX2018009100A (es) | 2016-01-26 | 2017-01-26 | Metodos para modular la flora intestinal. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190111107A1 (enExample) |
| EP (1) | EP3407905B1 (enExample) |
| JP (1) | JP6890135B2 (enExample) |
| KR (1) | KR20180121489A (enExample) |
| CN (1) | CN108778309A (enExample) |
| AU (1) | AU2017212534A1 (enExample) |
| BR (1) | BR112018015170A2 (enExample) |
| CA (1) | CA3012711A1 (enExample) |
| ES (1) | ES2871117T3 (enExample) |
| MX (1) | MX2018009100A (enExample) |
| RU (1) | RU2738265C2 (enExample) |
| SG (1) | SG11201805954WA (enExample) |
| WO (1) | WO2017129195A1 (enExample) |
| ZA (1) | ZA201804515B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2740913C2 (ru) | 2016-04-29 | 2021-01-21 | Дефенсин Терапьютикс Апс | Лечение нарушений со стороны печени, желчных путей и поджелудочной железы |
| CN111182915A (zh) | 2017-08-15 | 2020-05-19 | 金德雷德生物科学股份有限公司 | 兽药用IgG Fc变体 |
| DE102017219504A1 (de) | 2017-11-02 | 2019-05-02 | Bayerische Motoren Werke Aktiengesellschaft | Beleuchtungsvorrichtung für ein Kraftfahrzeug |
| KR20200095472A (ko) * | 2017-11-10 | 2020-08-10 | 디펜신 테라퓨틱스 에이피에스 | 조산아에서의 점막 방어 및 장/폐 기능의 성숙화 |
| MX2020005370A (es) * | 2017-11-24 | 2020-10-19 | Defensin Therapeutics Aps | Prevencion y tratamiento de enfermedad de injerto contra hospedero con defensinas. |
| JP7479381B2 (ja) * | 2019-01-07 | 2024-05-08 | アエスクルス バイオ エーピーエス | 治療または予防に使用するためのディフェンシン断片 |
| CN110447763B (zh) * | 2019-07-05 | 2023-01-20 | 江西农业大学 | 细菌在影响动物瘦肉率和/或脂肪含量中的应用 |
| CN114072071A (zh) * | 2019-07-19 | 2022-02-18 | 华盛顿大学 | 影响人类肠道微生物的组合物和方法 |
| CN111153982B (zh) * | 2020-02-17 | 2022-05-31 | 西北农林科技大学 | 一种反刍动物瘤胃特异抗菌肽defb1及其应用 |
| CN111202752A (zh) * | 2020-02-17 | 2020-05-29 | 上海市内分泌代谢病研究所 | 阿克曼氏菌组合物 |
| CN111635874B (zh) * | 2020-06-05 | 2022-03-18 | 江南大学 | 一株能够调控肠道阿克曼菌属相对丰度的脆弱拟杆菌 |
| KR102363092B1 (ko) * | 2020-06-19 | 2022-02-16 | 한국식품연구원 | 장내 미생물을 이용한 비만 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 비만 예방 또는 치료제 스크리닝 방법 |
| KR102363098B1 (ko) * | 2020-06-19 | 2022-02-16 | 한국식품연구원 | 장내 미생물을 이용한 신질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 신질환 예방 또는 치료제 스크리닝 방법 |
| CN111938158B (zh) * | 2020-08-18 | 2023-07-07 | 广东弘元普康医疗科技有限公司 | 一种防止肠道Akkermansia muciniphila菌丰度降低的组合物 |
| CN112121152B (zh) * | 2020-09-25 | 2021-06-22 | 南京大学 | 利司那肽在制备抗肿瘤药物中的应用 |
| CR20240137A (es) * | 2021-08-20 | 2024-07-29 | Biocad Joint Stock Co | Método para obtener una cápside de virus adenoasociado modificada |
| KR102740789B1 (ko) * | 2021-10-26 | 2024-12-11 | 가톨릭대학교 산학협력단 | 장내 마이크로바이옴을 이용한 천식의 중증도 및 복부비만 위험도 예측 방법 |
| CN115125167A (zh) * | 2022-06-15 | 2022-09-30 | 上海交通大学医学院附属瑞金医院 | 微生物组合及其用途 |
| CN114874311A (zh) * | 2022-06-20 | 2022-08-09 | 成都施桂行医药科技有限责任公司 | 防御肽及其制备方法和应用 |
| CN116268203B (zh) * | 2023-01-20 | 2024-08-20 | 中国农业大学 | 嗜黏蛋白阿克曼菌膜蛋白Amuc_1100在改善家禽蛋品质中的用途 |
| CN120535656B (zh) * | 2025-05-26 | 2025-12-12 | 中国农业大学 | 一种抗菌重组蛋白及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7528107B2 (en) * | 2005-11-30 | 2009-05-05 | Auburn University | Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins |
| WO2007133373A2 (en) * | 2006-05-01 | 2007-11-22 | England Robert L | TNF-α VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-α |
| WO2008115390A2 (en) * | 2007-03-16 | 2008-09-25 | The Hamner Institutes For Health Sciences | Methods of using defensins to treat diabetes |
| US20110311601A1 (en) * | 2010-06-22 | 2011-12-22 | Michael Kleine | Antimicrobial medical devices |
| JP6219277B2 (ja) * | 2011-07-08 | 2017-10-25 | ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ | 炎症性腸疾患の経口治療 |
| US20130052213A1 (en) * | 2011-08-19 | 2013-02-28 | Novozymes A/S | Novel immunomodulatory peptide |
| CN104971343B (zh) * | 2015-07-13 | 2018-02-02 | 韩源平 | 防御素在制备治疗代谢综合征药物方面的应用 |
-
2017
- 2017-01-26 KR KR1020187021406A patent/KR20180121489A/ko not_active Withdrawn
- 2017-01-26 MX MX2018009100A patent/MX2018009100A/es unknown
- 2017-01-26 AU AU2017212534A patent/AU2017212534A1/en not_active Abandoned
- 2017-01-26 JP JP2018557190A patent/JP6890135B2/ja not_active Expired - Fee Related
- 2017-01-26 EP EP17705790.8A patent/EP3407905B1/en active Active
- 2017-01-26 SG SG11201805954WA patent/SG11201805954WA/en unknown
- 2017-01-26 BR BR112018015170-0A patent/BR112018015170A2/pt not_active IP Right Cessation
- 2017-01-26 US US16/072,953 patent/US20190111107A1/en not_active Abandoned
- 2017-01-26 ES ES17705790T patent/ES2871117T3/es active Active
- 2017-01-26 WO PCT/DK2017/050017 patent/WO2017129195A1/en not_active Ceased
- 2017-01-26 RU RU2018129160A patent/RU2738265C2/ru active
- 2017-01-26 CA CA3012711A patent/CA3012711A1/en not_active Abandoned
- 2017-01-26 CN CN201780017713.0A patent/CN108778309A/zh active Pending
-
2018
- 2018-07-06 ZA ZA2018/04515A patent/ZA201804515B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017212534A1 (en) | 2018-07-26 |
| RU2018129160A3 (enExample) | 2020-05-29 |
| WO2017129195A1 (en) | 2017-08-03 |
| EP3407905A1 (en) | 2018-12-05 |
| JP2019504122A (ja) | 2019-02-14 |
| ZA201804515B (en) | 2021-01-27 |
| RU2018129160A (ru) | 2020-02-27 |
| SG11201805954WA (en) | 2018-08-30 |
| KR20180121489A (ko) | 2018-11-07 |
| RU2738265C2 (ru) | 2020-12-11 |
| CA3012711A1 (en) | 2017-08-03 |
| US20190111107A1 (en) | 2019-04-18 |
| JP6890135B2 (ja) | 2021-06-18 |
| ES2871117T3 (es) | 2021-10-28 |
| CN108778309A (zh) | 2018-11-09 |
| EP3407905B1 (en) | 2021-02-17 |
| BR112018015170A2 (pt) | 2018-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009100A (es) | Metodos para modular la flora intestinal. | |
| PH12019501216A1 (en) | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists | |
| MX2018000362A (es) | Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon. | |
| MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
| MX2016013244A (es) | Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon. | |
| MX2016013248A (es) | Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4. | |
| JOP20160092B1 (ar) | علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية | |
| MX2016013243A (es) | Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4. | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| MX2015008079A (es) | Agonista duales de glp1/gip o trigonales de glp1/gip/glucagon. | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| PE20151808A1 (es) | Peptidos terapeuticos | |
| EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
| BR112017007817A2 (pt) | tratamento do câncer com estimuladores imunológicos | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| BR112017013300A2 (pt) | alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições. | |
| MX377438B (es) | Administracion de tasimelteon en condiciones de ayuno. | |
| CY1122508T1 (el) | Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου | |
| BR112018074299A2 (pt) | composições farmacêuticas compreendendo eteplirsen | |
| ZA202001568B (en) | Methods and compositions for treating chronic lung diseases | |
| MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
| BR112017008621B8 (pt) | Composição alimentícia para promover massa corporal magra, minimizar o ganho de gordura corporal e manter o peso sem limitar a ingestão calórica em um animal | |
| MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. |